ADAGE CAPITAL PARTNERS GP, L.L.C. - ARROWHEAD PHARMACEUTICALS IN ownership

ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 278 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.

Quarter-by-quarter ownership
ADAGE CAPITAL PARTNERS GP, L.L.C. ownership history of ARROWHEAD PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$2,768,550
-34.2%
103,035
-12.7%
0.01%
-33.3%
Q2 2023$4,209,128
+88.9%
118,035
+34.6%
0.01%
+80.0%
Q1 2023$2,228,063
-42.5%
87,719
-8.2%
0.01%
-44.4%
Q4 2022$3,874,251
+809.4%
95,519
+640.5%
0.01%
+800.0%
Q3 2022$426,000
-6.2%
12,8990.0%0.00%0.0%
Q2 2022$454,000
-58.2%
12,899
-45.3%
0.00%
-50.0%
Q1 2022$1,085,000
-88.3%
23,599
-83.1%
0.00%
-88.2%
Q4 2021$9,282,000
+6.2%
140,0000.0%0.02%0.0%
Q3 2021$8,740,000
-29.6%
140,000
-6.7%
0.02%
-29.2%
Q2 2021$12,423,000
+368.4%
150,000
+275.0%
0.02%
+380.0%
Q1 2021$2,652,000
-77.0%
40,000
-73.3%
0.01%
-80.0%
Q4 2020$11,510,000
+167.3%
150,000
+50.0%
0.02%
+127.3%
Q3 2020$4,306,000
-20.2%
100,000
-20.0%
0.01%
-21.4%
Q2 2020$5,399,000
+25.1%
125,000
-16.7%
0.01%
+7.7%
Q1 2020$4,316,000
-61.1%
150,000
-14.3%
0.01%
-51.9%
Q4 2019$11,100,000
-7.3%
175,000
-58.8%
0.03%
-6.9%
Q3 2019$11,977,000
-48.3%
425,000
-51.4%
0.03%
-50.0%
Q2 2019$23,188,000
-8.1%
875,000
-36.4%
0.06%
-7.9%
Q1 2019$25,231,000
+47.7%
1,375,0000.0%0.06%
+34.0%
Q4 2018$17,078,000
-1.0%
1,375,000
+52.8%
0.05%
+23.7%
Q3 2018$17,253,000
-15.6%
900,000
-40.1%
0.04%
-19.1%
Q2 2018$20,448,000
+88.6%
1,503,5000.0%0.05%
+88.0%
Q1 2018$10,840,0001,503,5000.02%
Other shareholders
ARROWHEAD PHARMACEUTICALS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Western Financial Corp/CA 820,320$33,272,17921.56%
Aquilo Capital Management, LLC 1,103,515$44,758,56816.81%
M28 Capital Management LP 143,900$5,836,5845.56%
WEALTH EFFECTS LLC 155,620$6,311,9513.60%
Evolutionary Tree Capital Management, LLC 92,095$3,735,3733.59%
Privium Fund Management B.V. 221,015$8,867,1223.36%
JOHNSON & JOHNSON 247,598$10,0432.92%
COMMODORE CAPITAL LP 462,111$18,7432.82%
Avidity Partners Management LP 1,375,000$55,770,0001.21%
Capital Impact Advisors, LLC 26,853$1,089,1581.06%
View complete list of ARROWHEAD PHARMACEUTICALS IN shareholders